Senores Pharmaceuticals files FY26 sustainability report with exchanges
- Senores Pharmaceuticals filed its FY26 BRSR with BSE and NSE on September 3, 2026
- Turnover stood at ₹10,609 lakh with exports contributing 43.95% of revenue
- Total energy consumption rose to 22.50 TJ from 2.43 TJ in the prior year
- Related-party sales increased to 48.2% while purchases fell to 3.2%
- GHG emissions reached 1,738 metric tonnes of CO2 equivalent
*this image is generated using AI for illustrative purposes only.
Senores Pharmaceuticals has submitted its Business Responsibility and Sustainability Report (BRSR) for FY26 to the BSE and NSE. The filing, dated September 3, 2026, discloses standalone operational and environmental metrics for the financial year ended March 31, 2026.
The company reported a turnover of ₹10,609 lakh and a net worth of ₹74,990 lakh during the period. CSR provisions under Section 135 of the Companies Act, 2013 were applicable.
Operational Footprint
Senores operates two plants and five offices across India, serving customers in six international markets alongside pan-India distribution. Exports contributed 43.95% of total turnover in FY26. The workforce comprises 329 permanent employees and 111 workers.
Environmental Metrics
The report highlights significant increases in resource consumption compared to the prior year. Total energy consumption rose to 22.50 TJ, up from 2.43 TJ in FY25. Water withdrawal increased to 12,605 KL from 3,188 KL.
| Metric | FY26 | FY25 |
|---|---|---|
| Total Energy Consumption (TJ) | 22.50 | 2.43 |
| Water Withdrawal (KL) | 12,605 | 3,188 |
| GHG Emissions (Scope 1+2, MT CO2e) | 1,738 | 362 |
| Waste Generated (MT) | 47.36 | 7.88 |
Scope 1 and Scope 2 greenhouse gas emissions totaled 1,738 metric tonnes of CO2 equivalent, a rise from 362 metric tonnes in FY25. The company implemented Zero Liquid Discharge at its Kadi plant.
What the Numbers Show
Related-party transactions shifted significantly between sales and purchases. Sales to related parties surged to 48.2% of total sales in FY26, up from 3.6% in FY25. Conversely, purchases from related parties dropped to 3.2%, down from 25.4% previously. This divergence suggests a structural change in how the company sources inputs versus distributes outputs within its group structure.
Historical Stock Returns for Senores Pharmaceuticals
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -1.32% | -4.30% | +9.55% | +86.74% | +105.37% | 0.0% |
How will Senores Pharmaceuticals mitigate the sharp increase in energy consumption and GHG emissions to meet future regulatory compliance and sustainability targets?
What strategic factors drove the significant shift in related-party transactions, specifically the surge in sales to related parties while purchases from them declined?
Will the implementation of Zero Liquid Discharge at the Kadi plant be scaled to other facilities to address the overall rise in water withdrawal and waste generation?
15
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
